Adverse event reports following yellow fever vaccination-Reference-Cited by-同舟云学术

Adverse event reports following yellow fever vaccination

Published:2008-11 Issue:48 Volume:26 Page:6077-6082
ISSN:0264-410X
Container-title:Vaccine
language:en
Short-container-title:Vaccine

Author:

Lindsey Nicole P.,Schroeder Betsy A.,Miller Elaine R.,Braun M. Miles,Hinckley Alison F.,Marano Nina,Slade Barbara A.,Barnett Elizabeth D.,Brunette Gary W.,Horan Katherine,Staples J. Erin,Kozarsky Phyllis E.,Hayes Edward B.

Publisher

Elsevier BV

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,General Veterinary,General Immunology and Microbiology,Molecular Medicine

Reference42 articles.

1. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002;Cetron;MMWR Recomm Rep,2002

2. Yellow fever vaccine;Monath,2004

3. Comparison of the immunogenicity and safety of two 17D yellow fever vaccines;Lang;Am J Trop Med Hyg,1999

4. Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial;Monath;Am J Trop Med Hyg,2002

5. Immunogenicity and safety of BERNA-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial;Pfister;Am J Trop Med Hyg,2005

Cited by 219 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and immunogenicity of the yellow fever vaccine for patients with end-stage renal disease;Brazilian Journal of Nephrology;2024-12

2. Segurança e imunogenicidade da vacina contra febre amarela para pacientes com doença renal em estágio terminal;Brazilian Journal of Nephrology;2024-12

3. Adverse events following immunization (AEFI) with fractional one-fifth and one-half doses of yellow fever vaccine compared to full dose in children 9–23 months old in Uganda, 2019–2020 — Preliminary report;Vaccine;2024-09

4. The roles of CD4+ T cell help, sex, and dose in the induction of protective CD8+ T cells against a lethal poxvirus by mRNA-LNP vaccines;Molecular Therapy - Nucleic Acids;2024-09

5. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model;Cell Reports Medicine;2024-07